Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for Intrapartum Fetal Distress
NCT06522854Phase 3Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ASP-001 in Non-reassuring fetal status (NRFHT), Neonatal Asphyxia and intrapartum asphyxia (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Percentage of perinatal mortality at 96 hours, Percentage of use of bag and mask in neonates after delivery and 2 more. Planned start May 2025; status: withdrawn.
02
Drugs
ASP-001
03
Conditions
Non-reassuring fetal status (NRFHT)Neonatal Asphyxiaintrapartum asphyxia
Beyond the preview
Go deeper on NCT06522854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522854.